Caplacizumab is a humanized anti-von Willebrand factor (vWF) antibody that inhibits interaction between vWF multimers and platelets. Caplacizumab can be used for the treatment of thrombotic thrombocytopenic purpura (TTP).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.